Ledger · 2026-08-31 · Cosmeceuticals / Therapeutics

Enzymatic Cyclic Phosphatidic Acid (cPA) via Biocatalytic Transphosphatidylation

Rejected

This concept did not clear the framework. The reasoning is published in full below.

Why it failed

• Voided by: Negative control / sub-2x

Assessment

cPA fails superiority and incumbent legitimacy under Sub-test E because exogenous Hyaluronic Acid is inherently incapable of inducing endogenous HA synthesis, making it an untreated negative control (0 ng/ml) for that specific biological pathway rather than a legitimate benchmark for synthesis induction.

Claimed advantage

Categorical capability (0 to >200ng/ml) in endogenous HA synthesis induction vs exogenous HA

Named comparator: Exogenous Hyaluronic Acid

Also flagged

• Evidence rests on non-peer-reviewed sources
• Duplicate references inflating the evidence base
• Price parity asserted, not sourced
• no_production_runsheet
• unsourced_equipment
• no_opex

A rejection is not a claim that the science is wrong. It means the venture case did not survive: the comparator was not what the buyer actually buys, the comparison was not like-for-like, the advantage fell short of a step change, or the capital and time to first revenue were prohibitive.

---

Assessed 2026-08-31 against seven gates plus the voiding sub-tests. How the method works · Browse all concepts